ELEVAI Labs Expands Into European Market With Signing of New Partnership
The Company's New Strategic Partnership With Premier Luxury Skincare Distributor Skin Sana Ltd. Will See ELEVAI Enter the European Market With its Topical Exosome Skincare Products
ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partnership with Skin Sana Ltd. a Serbian corporation and premier luxury skincare distributor based in Belgrade covering territories that include Serbia, Albania, North Macedonia, Kosovo and Bosnia-Herzegovina. This strategic collaboration is the company’s first in Europe and marks the beginning of a robust relationship bringing ELEVAI’s topical exosome products to the region.
Chris Kraneiss, Chief Commercial Officer of ELEVAI Labs commented on the company’s new partnership, stating:
“We are thrilled to announce our strategic expansion into Europe, marking a significant milestone in our global distribution strategy. Our new business partner, Skin Sana Ltd. is partnering with some of the most seasoned professionals in plastic surgery, dermatology, aesthetics, and laser surgery in these territories, including Dr. Aleksandra Markoski Smiljkovic. We are poised to bring our skincare solutions to enhance the beauty and well-being of individuals across the continent.”
Source: ELEVAI Skincare YouTube
Also Read: ELEVAI Labs Closes $6 Million NASDAQ IPO
Also commenting on the new strategic collaboration, Skin Sana CEO Vera Petkovic had the following to say:
“We are excited to partner with Elevai and be the first in Europe to distribute their innovative exosome products. We believe that Elevai’s exosome products have the potential to revolutionize the way we address a wide range of aesthetic concerns.”
Dr. Aleksandra Markoski Smiljkovic, CEO and founder of Rejuva Laser and Aesthetic Belgrade in Serbia, remarked on becoming the first Serbian clinic to offer its patients ELEVAI’s innovative topical exosome products, stating:
“I am excited to be the first clinic in Serbia to offer Elevai’s innovative topical exosome products to my patients. I have been impressed with the results of Elevai’s products that I tested, and I am excited to see the results that we can achieve in my clinic. I believe that Elevai’s exosome products are the future of medical aesthetics and I am proud to be a part of this groundbreaking technology.”
Shares of ELEVAI Labs (NASDAQ: ELAB) last traded at $2.13 per share.
Learn more about ELEVAI Labs: Website | Investor Deck | ELAB Chart
Follow ELEVAI on Social Media: Instagram | LinkedIn | Facebook | Twitter | YouTube
Join the Discussion in the Wealthy VC Investor Group
Have a Stock Tip or New Story Suggestion? Email us at Invest@WealthyVC.com
Elevai Labs Inc. is a paid client of Wealthy VC.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
